A structure-activity relationship study was attempted to determine the structural specificity of the no. 8 amino acid residue of [l-asp.,5-ileu]-angiotensin II for adrenal medullary stimulation. Isolated cat adrenal glands were perfused retrograde at a flow rate of 1 ml/min with phosphate-buSered Locke's solution at 23 to 25 C, Continuous catecholamine analysis was performed using an automated trihydroxyindole procedure. All drugs were administered either by single injection (0.05 to 0. In vitro studies with 10-leu-C 14 -angiotensin I and angiotensin II antibody indicated that angiotensin I has a marked, direct stimulatory effect on the adrenal medulla. Adrenal medullary catecholamine secretion induced by angiotensin I and II was greatly potentiated by DMAE perfusions. Responses to nicotine were blocked by DMAE and bradykinin-indueed catecholamine release was unchanged. The cross-tachyphylaxis and DMAE studies suggest that several of the analogues and angiotensin II are interacting with a common adrenal medullary receptor. 
Three peptides (angiotensin II, [8-tyr] -angiotensin II, and [8-ala]-angiotensin II) were studied in vivo for stimulation of adrenal catecholamine secretion. For maximum pressor activity, angiotensin must be an octapeptide with an aromatic amino acid and free COOH group in the no. 8 position. None of these three are structural requirements in adrenal chromaffin tissue. There was cross-tachyphylaxis between angiotensin II and all the analogues studied except two ( [8 
-APBJ-and [8-APIB]-angiotensin II).
In vitro studies with 10-leu-C 14 -angiotensin I and angiotensin II antibody indicated that angiotensin I has a marked, direct stimulatory effect on the adrenal medulla. Adrenal medullary catecholamine secretion induced by angiotensin I and II was greatly potentiated by DMAE perfusions. Responses to nicotine were blocked by DMAE and bradykinin-indueed catecholamine release was unchanged. The cross-tachyphylaxis and DMAE studies suggest that several of the analogues and angiotensin II are interacting with a common adrenal medullary receptor.
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• Angiotensin II has been reported to stimulate the adrenal medulla in vivo, 1 in situ, 2 and in vitro. 3 Structure-activity relationship studies have also been reported with angiotensin II and adrenal catecholamine secretion; 4 -5 the activities of analogues in the adrenal were approximately equal to activities found with vasopressor assays. In two recent studies, several 8-substituted analogues of angiotensin II were found to have activities in the isolated perfused rabbit heart 6 and isolated guinea pig ileum 7 that were markedly different from their oxytocic and pressor activities. In view of these findings, it was of interest to expand the studies on structure-activity for angiotensin and adrenal catecholamine release.
In the present investigation, a structureactivity study was attempted in isolated, retrograde-perfused adrenals with C-tenninussubstituted analogues of angiotensin II to 11-107
11-108
PEACH determine the structural requirements for medullary stimulation. Some analogues were also studied in vivo for adrenal catecholamine release. Attempts were made to show that these analogues of angiotensin and the parent peptide interacted with the same adrenal medullary receptor.
Methods
Mongrel cats of eidier sex with weights ranging from 1.0 to 2.8 kg were anesthetized with intravenous pentobarbital-Na (30 mg/kg) and administered intravenous heparin-Na (500 units/ kg). A midline incision was made from the base of the sternum to the pelvis and one or both adrenal glands exposed. Most experiments were performed with the left adrenal; however, some experiments were done with the right gland. Ligatures were placed around the adrenolumbar vein distal to the adrenal and between the adrenal and the inferior vena cava. A 27 G pediatric scalp vein infusion set needle (with 2 to 3 cm of cannula still attached) was inserted into the adrenolumbar vein distal to the gland and secured by ligature. The adrenal was rapidly excised and connected via the cannula to a Technicon AutoAnalyzer pump for retrograde perfusion. All extraneous tissue was dissected from the gland. Glands were perfused at room temperature (23 to 25 C) at a flow rate of 0.9 to 1.0 ml/min with phosphate-buffered Locke's solution equilibrated with oxygen.
The effluent from the gland was collected in a 4-ml reservoir and continuously analyzed for catecholamines at pH 7.0 by the automated trihydroxyindole procedure of Robinson and Watts. 8 The analytical procedure for total catecholamines and differential estimation of epinephrine and norepinephrine was as described by Robinson. 3 All adrenal glands were allowed to reach a constant level of spontaneous catecholamine output (usually about one hour) before any drugs were administered.
Locke's solution was the vehicle for all drugs injected in vitro, and all injection volumes were 0.05 to 0.1 ml. Injections were made with 27-28 G needles through surgical tubing connecting the perfusion line to the gland. None of the peptides administered had any effect on the fluorometric analytical procedure. Drugs were administered at 20-to 30-minute intervals to avoid development of tachyphylaxis. Peptides administered via injection were in doses from 10~1 2 to 10~5 moles. Peptides studied were: [5- 8 Column recoveries of added catecholamines were 70% to 75%. The data are not corrected for the 20% to 25% amine lost during these procedures.
To determine whether adrenal medullary stimulation induced by angiotensin I was direct or indirect (via conversion to angiotensin II), studies were performed with 10-leu-C 14 -angiotensin I. Radiochemical purity of stock labeled peptide was 95%, with a specific activity of 2.5 X 10 6 dpm//unole. An Arnicon Diaflo filter no. UM05 with a molecular weight cutoff of 500 was used to filter C 14 -angibtensin I from solution. Concentrations of 10~9 to 10" 5 moles C 14 -decapeptide in 10 to 20 ml of oxygenated Locke's solution and 10" 3 M ethylenediaminetetraacetate (EDTA) were placed in a 50-ml Diaflo chamber (23 to 25 C and 50 psi) and filtered. Filtrates were collected at 15 and 30 minutes and 1-ml aliquots were added to 15 ml of scintillation cocktail (POP, POPOP, 2:1 toluene-Triton X-100) and counted (counting efficiency 95% to 96%). To establish if passage of the dipeptide (his-C 
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tensin I (10~9 to lCh 5 moles) was incubated at room temperature with 10 to 20 ml of cat plasma. Incubation was terminated after 30 minutes by addition of EDTA (final concentration 10-3 M) and the samples were then placed on ice.
Incubates were filtered at 4 C and filtrates sampled and counted as described above. Retrograde-perfused adrenals were injected with C 14 -angiotensin I and the effluent from the gland •collected in EDTA. The effluent was collected for 15 or 30 minutes after injection of C 14 -decapeptide, filtered, sampled, and counted.
Another method of approach utilized the specificity of antigen-antibody interaction. Antibody to angiotensin II prepared by immunizing rabbits with {l-asp,5-ileu]-angiotensin II coupled to bovine albumin by the carbodimide method of Goodfriend et al. 9 was used.* Antibody alone, or in combination with angiotensin II or angiotensin
•Supplied by Dr. P. A. Khairallah of the Research Division of the Cleveland Clinic, Cleveland, Ohio. I, was injected to the adrenal gland in vitro and secretion of catecholamines determined. The antibody had no effect on the fluorometrie assay for catecholamine. It was experimentally determined by dog and rat blood pressure assay that 1 ml of antibody neutralized 2 ug of angiotensin II.
In some experiments, angiotensin was added to oxygenated Locke's solution (final concentration 10^7 to 10" 6 moles/min) and continuously perfused through the adrenal for 15 to 30 minutes to induce tachyphylaxis. If responses to nicotine were not the same before and alter induction of angiotensin tachyphylaxis, the preparation was discarded. Peptddes were studied 1 for erosstaohyphylaxis with angiotensin II in the retrograde-perfused adrenal.
Studies on the specificity of the potentiation of angiotensin-induced adrenal catecholamine release produced by a,a'-bis-(dimethylammoniumacetaldehyde diethylacetal) -p,p'-diacetylbiphenyl bromide (DMAE) were performed. Peptides and nicotine were studied in the isolated adrenal before and during the administration of DMAE via perfusion (100 /Ag/min).* Statistical analysis of data was performed using Student's r-test.
Results
The effects of angiotensin II and analogues on total catecholamine secretion from the isolated adrenal are shown in Figure 1 . These percentages of relative activity can be contrasted with those for pressor activity which are shown in Figure 1 after the name of each peptide. In vivo adrenal catecholamine secretion induced by angiotensin II and two of the analogues studied in vivo are presented in Figure 2 . Mean plasma catecholamine levels were significantly elevated for five minutes postinjection (P<0.01). The greatest increase in adrenolumbar venous catecholamine levels occurred at two minutes after intravenous administration of the peptides. By six minutes after injections, the induced elevation of plasma catecholamine levels had returned to control levels. Figure 3 . The ratio of epinephrine: norepinephrine in the spontaneous secretion from the glands was 78±4%:23±3.6% and did not differ between the left and right adrenal glands. This ratio of epinephrine:norepinephrine was approximately 75%: 25% during an induced secretory response with any of the peptides studied regardless of the dose administered or whether the left or right gland was studied. Over the range of doses shown in the figure, there was no difference in induced secretion of catecholamines obtained in response to injections of angiotensin I, angiotensin II, or angiotensin II-amide.
Studies with 10-leu-C 14 -angiotensin I are summarized in Figure 4 . Diaflo UM05 filters were studied for effectiveness in filtering C 14 -angiotensin I from Locke's solution. This filter effectively blocked the passage of decapeptide at all three concentrations studied (10" 9 to 10~5 mmoles). About 10% of the C u activity added passed through the filter. After 30 minutes' incubation with plasma converting enzyme at 25 C to split off the dipeptide (his-C 14 -leu), radioactivity readily filtered through the 500-molecular-weight filter. Approximately 90% of the C 14 activity added to plasma was recovered in the filtrate from the 30-minute incubate. Effluents collected from the adrenal after injection of C^-angiotensin I were also filtered. Filterable C"-peptide in these effluents was not greater than in control experiments. About 85$ to 90$ of the C 14 -angiotensin I administered to the perfused adrenal was present in the effluent collected. The remaining 10$ was sequestered by the gland. Even if one assumes that ah" the radioactivity retained in the adrenal represents histidyl-C catecholamines induced by angiotensin II was blocked by angiotensin II antibody. Adrenal medullary responses to angiotensin I were identical in the presence or absence of angiotensin II antiserum. All glands still responded to angiotensin I and II administration after washout of antibody or antibodypeptide complexes. In 12 experiments the antibody totally blocked responses to angiotensin II (10" 11 to KH moles), but had no effect on responses to angiotensin I (HH 1 to 1(H moles). The effects of DMAE administration on adrenal responses to nicotine, bradykinin, angiotensin II, and angiotensin I are presented in Table 1 . The perfusion of DMAE had no effect on responses to bradykinin and totally blocked responses to nicotine (P < 0.01). Catecholamine secretion induced by angiotensin I or angiotensin II was markedly potentiated by the concomitant administration of DMAE (P<0.01).
Effects of adrenal medullary tachyphylaxis induced by [l-asp,5-ileu]-angiotensin II on responses to [l-asp,S-deu]-angiotensin II and nicotine. Total catecholamine secretion is

Discussion
In the present study, seven angiotensin II analogues with alterations in the no. 8 position were studied. All of these compounds had identical peptide structures at positions 1 through 7. Of these analogues, five had much greater activities with adrenal medullary than with vascular smooth muscle assay. The effects of angiotensin II and two of these peptides ( Angiotensin I has been reported to have very little biological activity on vascular smooth muscle, 10 uterus, 11 perfused kidney, 12 or norepinephrine uptake. 6 Data presented here showed a marked release of adrenal catecholamines following the administration of angiotensin I. Studies with 10-leu-C 14 -angiotensin I and/or octapeptide antiserum indicated that no significant intra-adrenal conversion of angiotensin I occurs, and that angiotensin I has a direct stimulatory effect on adrenal chromaffin tissue. Renin administration has been shown to be accompanied by catecholamine release, 4 but any contribution of angiotensin I to this response has not been reported previously.
In a previous structure-activity study 4 of angiotensin and the adrenal medulla, fragments of the peptide chain (hexa-and heptapeptides), substitutions of amino acid positions 1 or 4, and sequence variations among positions 5 through 9 (nonapeptide) or 5 through 10 (decapeptide) were investigated. The nonapeptides and decapeptides studied were not naturally occurring decapeptide or fragments of angiotensin I. A study was also reported by Staszewska-Barczak and Konopka-Rogatko 5 in which they studied substitutions of amino acid residues 1, 2, 4, and 6. Both these reports 4 -5 showed good correlation between pressor activity of each
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analogue and the release of catecholamines from the adrenal. On the basis of these studies, the conclusion was made that the structural requirements of angiotensin II in vascular smooth muscle and the adrenal medulla were identical.
The structure-activity relationships of angiotensin II on vascular or uterine smooth muscle have recently been reviewed. 13 The following structural requirements have been established: (1) there must be at least 6 amino acids in the peptide chain (residues 3 to 8 of angiotensin II); (2) 8 amino acids are required for maximum activity; (3) a tyrosine residue must be present in position 4; (4) the imidazole ring of histidine may be required in position 6; (5) proline must be adjacent to the no. 8 amino acid; and (6) an aromatic amino acid and free carboxyl (COOH) are required in the no. 8 position.
With regard to the adrenal medulla, requirements 1, 3, and 4 listed above for pressor or oxytocic activity have been shown to correlate very well. 4 ' 5 The requirement of the no. 8 amino acid (no. 6 of the requirements enumerated above) for adrenal catecholamine release has not previously been reported. The data presented here have shown the following not to be structural requirements for adrenal catecholamine release: (1) the octapeptide chain; (2) aromatic nucleus in no. 8 position; and (3) free COOH in no. 8 position. The marked activity of angiotensin I on chromaffin tissue obviates the necessity of 8 amino acid residues for maximum activity. The no. 8 position aromatic amino acid is not an absolute structural requirement since [8-ala]-angiotensin II (O.1SS pressor activity) was 25% as active as angiotensin II. A free COOH (no. 8 position) is not needed in the adrenal medulla based on the activities displayed by angiotensin I and tetradecapeptide. Both angiotensin I and tetradecapeptide have Cterminus free COOHs, however, on leucine (2 amino acid residues removed from the no. 8 position) or on serine (6 residues removed).
To suggest receptor analysis based on a structure-activity relationship study, one must assume or establish that the parent compound and its congeners produce a common response via interaction with an identical receptor. If the postulate that angiotensin tachyphylaxis is due to partial or complete receptor saturation 14 is accepted and the angiotensin-receptor schematic proposed by Khairallah et al. 7 is followed, the conclusion can be made that the occurrence of cross-tachyphylaxis indicates the same specific receptor site is involved in initiating responses to angiotensin II and its analogues. On the other hand, the absence of cross-tachyphylaxis between an analogue and a parent compound is difficult to evaluate. Additional proof that structural analogues are interacting with a common receptor might be based on the specificity of pharmacological antagonism or potentiation of responses. In the present structure-activity study, crosstachyphylaxis was one criterion established to evaluate the specificity of angiotensin receptors in adrenal chromaffin tissue. The use of DMAE to potentiate selectively adrenal medullary responses to angiotensin was examined, Greenberg and Long 15 have recently reported potentiation by DMAE of the sympathetic component of in vivo pressor responses to angiotensin II. In the isolated, retrogradeperfused adrenal, DMAE blocked responses to nicotine and had no effect on bradykinininduced catecholamine secretion. Adrenal catecholamine release in response to angiotensin I or II was markedly potentiated by DMAE. This hemicholinium congener (DMAE) may well be a very useful tool in determining the specificity of chromaffin tissue receptors that respond to angiotensin analogues. All the 8-substituted analogues used in this investigation, with the exception of [8-APB]-and [8-APIB]-angiotensin II, exhibited cross-tachyphylaxis with angiotensin II.
The data presented here (plus angiotensin structure-activity studies of isotonic contractions and stimulation of parasympathetic neurons in isolated intestine, 7 inhibition of myocardial norepinephrine uptake, 6 vasopressor and oxytocic responses 13 ) indicate that the angiotensin receptor sites in vascular (or uterine) smooth muscle, in the sympatho- 
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PEACH adrenal system, and in parasympathetic nerves are different.
